Consensus Genmab A/S London S.E.

Equities

0MGB

DK0010272202

Real-time Estimate Cboe Europe Other stock markets 15:36:30 01/07/2024 BST			5-day change	1st Jan Change
1,735 ^DKK	-0.13%		-3.56%	-18.22%

06-28	Would you like some more inflation?
06-28	Genmab, AbbVie's Lymphoma Therapy Recommended for Approval in EU	MT

Evolution of the average Target Price on Genmab A/S

Price target over the last 5 years

History of analyst recommendation changes

78bd.A5hati4dn8Z60SqTVlR8qO_QzrYPBsnBhFUuR5KKjZ8.d8cP3Vlcybw4h0TaMi4Jxb6dnM9FcKur6QdrLt7S4elA8j30XkSqpS6UYw~4518da003f5a2c5c4e3508a97f787aef

Analyst Recommendations on Genmab A/S

BTIG Adjusts Price Target on Genmab to $47 From $46, Maintains Buy Rating	06-27	MT
Truist Securities Raises Price Target on Genmab to $53 From $50, Maintains Buy Rating	06-04	MT
GENMAB : A good start to 2024; guidance unchanged	05-03
GENMAB : Genmab is available at a bargain price	03-04
BMO Capital Upgrades Genmab to Outperform From Market Perform, Adjusts Price Target to $48 From $46	02-23	MT
RBC Cuts Price Target on Genmab to DKK2,400 From DKK2,500, Keeps Sector Perform Rating	02-21	MT
GENMAB : A profitability miss but the market welcomed the better-than-expected sales guidance + share buybacks	02-15
HC Wainwright Raises Price Target on Genmab to $50 From $49, Maintains Buy Rating	01-29	MT
Morgan Stanley Adjusts Price Target on Genmab to $32 From $33, Maintains Underweight Rating	11-09	MT
HC Wainwright Adjusts Price Target on Genmab to $49 From $51, Maintains Buy Rating	11-08	MT
GENMAB : Better-than-expected Q3; lower-end of sales guidance upgraded	11-08
GENMAB : Factoring in some caution	31/10/23
BTIG Raises Price Target on Genmab to $46 From $44, Maintains Buy Rating	13/10/23	MT
GENMAB : Incorporating R&D priorities; attractiveness remains intact	25/08/23
BTIG Starts Genmab at Buy With $44 Price Target	24/08/23	MT
GENMAB : A good Q2 + improved sales guidance	04/08/23
HC Wainwright Adjusts Price Target on Genmab to $51 From $47, Keeps Buy Rating	22/05/23	MT
HC Wainwright Adjusts Price Target on Genmab to $47 From $46, Maintains Buy Rating	16/05/23	MT
GENMAB : Mixed Q1; attractiveness remains intact, despite profitability miss	11/05/23
GENMAB : Promising 2022; even the softer 2023 guidance isn’t a worry	20/03/23
HC Wainwright Adjusts Price Target on Genmab to $46 From $51, Maintains Buy Rating	02/03/23	MT
Morgan Stanley Trims Price Target on Genmab to $33 From $34, Maintains Underweight Rating	01/03/23	MT
GENMAB : Promising 2022; even softer 2023 guidance isn’t a worry	23/02/23
Morgan Stanley Adjusts Price Target on Genmab to $34 From $35, Keeps Underweight Rating	23/02/23	MT
SVB Securities Adjusts Price Target on Genmab A/S to $36 From $33, Maintains Market Perform Rating	06/02/23	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1,745 DKK

Average target price

2,464 DKK

Spread / Average Target

+41.20%

High Price Target

3,000 DKK

Spread / Highest target

+71.92%

Low Price Target

1,600 DKK

Spread / Lowest Target

-8.31%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Genmab A/S

Truist Securities
alphavalue	Anas Patel
BMO Capital
RBC Capital Markets
HC Wainwright
Morgan Stanley
BTIG
SVB Securities LLC
William Blair & Co.
DNB Markets
Credit Suisse
Bryan, Garnier & Co.
Cowen
SVB Leerink
Guggenheim
Berenberg Bank
Jefferies & Co.
Deutsche Bank Securities
Danske Bank Group

Ratings for Genmab A/S

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar